# Phase IIIB Switching From Intravenous to Subcutaneous Study

> **NCT00663702** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 123 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Abatacept

## Key facts

- **NCT ID:** NCT00663702
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-12
- **Final completion:** 2012-01
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2015-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00663702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00663702, "Phase IIIB Switching From Intravenous to Subcutaneous Study". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00663702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*